source
- Cerevance reports positive Phase 3 results for Parkinson’s drug solengeprasCerevance, a Boston biotech spinout from Takeda, announced that its experimental Parkinson’s drug solengepras achieved its primary endpoint in a Phase 3 trial. The trial enrolled 341 patients with…
- Dutch court blocks Merck's subcutaneous Keytruda sales in eight European countries after Halozyme patent winA Netherlands court issued an injunction that stops Merck from marketing its subcutaneous formulation of Keytruda, known as Keytruda Qlex, in eight European markets. The ruling follows a patent in…